Bioplus Acquisition Corp Stock Current Valuation
Valuation analysis of BioPlus Acquisition Corp helps investors to measure BioPlus Acquisition's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
BioPlus Acquisition Corp Company Current Valuation Analysis
BioPlus Acquisition's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current BioPlus Acquisition Current Valuation | 215.16 M |
Most of BioPlus Acquisition's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioPlus Acquisition Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, BioPlus Acquisition Corp has a Current Valuation of 215.16 M. This is 99.34% lower than that of the Capital Markets sector and significantly higher than that of the Financials industry. The current valuation for all United States stocks is 98.71% higher than that of the company.
BioPlus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioPlus Acquisition's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioPlus Acquisition could also be used in its relative valuation, which is a method of valuing BioPlus Acquisition by comparing valuation metrics of similar companies.BioPlus Acquisition is currently under evaluation in current valuation category among its peers.
BioPlus Fundamentals
| Return On Asset | -0.0072 | |||
| Current Valuation | 215.16 M | |||
| Shares Outstanding | 19.37 M | |||
| Shares Owned By Insiders | 48.69 % | |||
| Shares Owned By Institutions | 51.31 % | |||
| Number Of Shares Shorted | 1.64 K | |||
| Price To Earning | (3.62) X | |||
| EBITDA | (1.17 M) | |||
| Net Income | 2 M | |||
| Cash And Equivalents | 294.69 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 5 M | |||
| Debt To Equity | 7.23 % | |||
| Current Ratio | 2.96 X | |||
| Book Value Per Share | (0.86) X | |||
| Cash Flow From Operations | (691.47 K) | |||
| Short Ratio | 0.03 X | |||
| Earnings Per Share | 0.21 X | |||
| Price To Earnings To Growth | (7.93) X | |||
| Target Price | 20.0 | |||
| Number Of Employees | 38 | |||
| Beta | 0.14 | |||
| Market Capitalization | 208.98 M | |||
| Total Asset | 238.32 M | |||
| Retained Earnings | (14.78 M) | |||
| Working Capital | 21.89 K | |||
| Current Asset | 183.69 M | |||
| Current Liabilities | 152.76 M | |||
| Z Score | 24.97 | |||
| Net Asset | 238.32 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in BioPlus Stock
If you are still planning to invest in BioPlus Acquisition Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BioPlus Acquisition's history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |